Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07063693 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ABY-029 Glioma Trial

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 31, 2026 to Feb 17, 2026
    v5
  2. Start date: Oct 31, 2025 to Jan 31, 2026v4
  3. Study title shortened, about 2 wordsv3
  4. Start date: Jul 31, 2025 to Oct 31, 2025
    • Study title shortened, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Trial Details
NCT Number NCT07063693
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Dartmouth College, National Cancer Institute (NCI)
Conditions
(from sponsor)		 Intracranial Tumor
Related terms Brain Neoplasms
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov